Moderate

Difficult-to-control asthma — systematic assessment

before escalating · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Most poorly controlled asthma is 'difficult' (modifiable factors) rather than truly 'severe'. A structured assessment of diagnosis, adherence, technique, comorbidities and exposures is mandatory before escalating therapy or labelling refractory disease.

Red flags

  • Frequent OCS courses or ICU/near-fatal episodes
  • Falling FEV1 or fixed airflow obstruction
  • Persistent eosinophilia or systemic features suggesting vasculitis
  • Haemoptysis, weight loss or finger clubbing (reconsider diagnosis)

Assessment

Differential diagnosis

  • Incorrect diagnosis (COPD, bronchiectasis, heart failure, ILO/VCD)
  • Poor adherence to controller therapy
  • Poor inhaler technique / wrong device
  • Ongoing allergen/occupational/smoke exposure
  • Untreated comorbidity (CRSwNP, GORD, OSA, obesity, anxiety)
  • Recurrent respiratory infection or ABPA

Investigations

  • Spirometry with bronchodilator reversibility; FeNO; peak-flow diary
  • Dispensing/prescription collection records to quantify adherence
  • Supervised inhaler technique assessment
  • Blood eosinophils, total IgE, Aspergillus serology
  • Chest X-ray; HRCT if bronchiectasis/ILD suspected
  • Screen comorbidities: nasendoscopy for polyps, OSA screen, reflux and mental-health assessment

Management

  • Re-confirm that it is asthma with objective evidence of variable airflow obstruction
  • Quantify adherence objectively — do not rely on self-report
  • Watch the patient use their inhaler and correct technique or switch device
  • Identify and remove triggers: smoking, vaping, occupational and domestic allergens
  • Systematically treat comorbidities (rhinosinusitis, GORD, obesity, OSA, dysfunctional breathing, anxiety)
  • Review medication for asthma-worsening drugs (NSAIDs, non-selective beta-blockers)
  • Optimise controller — ensure correct ICS-LABA dose and consider MART/AIR regimen
  • Provide a written personalised asthma action plan and self-management education
  • Reassess control (ACT/ACQ) after a defined optimisation period
  • Only if still uncontrolled with confirmed adherence/technique, refer as true severe asthma for phenotyping/biologics

Drugs & doses

ICS-LABA maintenance-and-reliever (e.g. budesonide-formoterol 200/6 mcg, 1-2 inhalations as needed/maintenance)
Add tiotropium 2.5 mcg (2 puffs) once daily as add-on LAMA
Montelukast 10 mg PO once daily as add-on
Short course prednisolone 40 mg PO once daily for exacerbations

Disposition

Primary care / general respiratory clinic for optimisation; refer to severe-asthma service only after modifiable factors addressed.

Complications & pitfalls

  • Unnecessary treatment escalation and steroid toxicity
  • Missed alternative diagnosis
  • Progressive airway remodelling from under-treatment
  • Repeated exacerbations and healthcare utilisation

Exam pearls

  • ~50% of 'severe' referrals are difficult-to-control with modifiable factors
  • Good adherence often means <50% of prescribed controller is actually taken
  • Dysfunctional breathing and ILO frequently coexist and mimic uncontrolled asthma
  • Document the optimisation trail before biologic funding applications

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.